FORM	4
------	---

Check this box if no
longer subject to Section
16. Form 4 or Form 5
obligations may
continue. See
Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)										
1. Name and Address of Reporting Person [*] KIM DENNIS D		2. Issuer Name and Ticker or Trading Symbol Emerald Bioscience, Inc. [EMBI]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director		
(Last) (First) 5910 PACIFIC CENTER BLVD, SUIT		3. Date of Earliest Transaction (Month/Day/Year) 08/07-05:00/2020								
(Street) SAN DIEGO, CA 92121	4	4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City) (State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned						l		
1. Title of Security 2. Transaction Date (Month/Day/Y		Execution Date, if any	Code		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s)		Beneficial
		(Month/Day/Year)	Code	V	Amount	(A) or (D)	Price	(Instr. 3 and 4)	Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

	(e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year)	Code	tion)	5. Number of 6 Derivative E		6. Date Exer Expiration I (Month/Day	Date	7. Title and Amount of Underlying Securities (Instr. 3 and 4)		Derivative Security (Instr. 5)	Securities Beneficially Owned Following	Ownership Form of Derivative	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date		Amount or Number of Shares		Transaction(s) (I) (Instr. 4) (Instr. 4)	< / s	
Employee Stock Option (Right to Buy)	\$ 0.045	08/07- 05:00/2020		A		4,000,000		<u>(1)</u>	08/07- 05:00/2030	Common Stock	4,000,000	\$ 0	4,736,541	D	

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
KIM DENNIS D 5910 PACIFIC CENTER BLVD SUITE 320 SAN DIEGO, CA 92121			Chief Medical Officer				

Signatures

/s/ Dennis D. Kim, MD	08/11-05:00/2020
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Each of the Options shall be exercisable for a price of \$0.045 per Option Share for ten years from August 7, 2020 (the "Grant Date") and all Options will vest 10% on the Grant Date and 90% in equal semiannual installments over four years.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.